Cowtown Angels

Cowtown Angels is an angel investment network established in 2012 and based in Fort Worth, Texas. Founded by TECH Fort Worth, a non-profit organization aimed at fostering economic development through technology startups, Cowtown Angels focuses on connecting emerging businesses with local investors. The organization not only facilitates introductions between angel investors and entrepreneurs but also provides coaching to help entrepreneurs navigate the funding process. By supporting startups, Cowtown Angels aims to contribute to job creation and wealth generation within the local community, positioning itself as one of the fastest-growing networks in the Angel Capital Association.

Ryan Brown

CEO

8 past transactions

Zylo Therapeutics

Series B in 2022
Zylo Therapeutics, Inc. is a life sciences company based in Greenville, South Carolina, specializing in a sustained-release drug delivery system. Founded in 2017, the company has developed a delivery mechanism that employs patented hydrogel-derived nanoparticles, known as Nanopods™, to facilitate the topical administration of difficult-to-deliver therapeutic agents, including nitric oxide. This innovative system enhances drug delivery capabilities and is designed to improve the treatment of various conditions such as lupus, hair loss, joint pain, and burns. By utilizing engineered amorphous silica particles, Zylo Therapeutics aims to provide a controlled and sustained release of medications, thereby enhancing product performance and patient outcomes.

VenoStent

Seed Round in 2021
VenoStent, Inc. is a biomaterials and bioengineering company based in Nashville, Tennessee, with an additional office in Houston, Texas. Established in 2017, the company specializes in developing bioresorbable smart polymers aimed at enhancing vascular surgery outcomes. Its primary product, SelfWrap, is a perivascular wrap designed to minimize complications at the junctions of veins and arteries, particularly for dialysis patients. SelfWrap functions as an external stent that promotes outward vein growth and provides mechanical support, thereby reducing the risk of vein collapse. By focusing on innovative solutions in vascular care, VenoStent aims to improve patient outcomes and transform surgical practices.

VenoStent

Seed Round in 2020
VenoStent, Inc. is a biomaterials and bioengineering company based in Nashville, Tennessee, with an additional office in Houston, Texas. Established in 2017, the company specializes in developing bioresorbable smart polymers aimed at enhancing vascular surgery outcomes. Its primary product, SelfWrap, is a perivascular wrap designed to minimize complications at the junctions of veins and arteries, particularly for dialysis patients. SelfWrap functions as an external stent that promotes outward vein growth and provides mechanical support, thereby reducing the risk of vein collapse. By focusing on innovative solutions in vascular care, VenoStent aims to improve patient outcomes and transform surgical practices.

VenoStent

Pre Seed Round in 2018
VenoStent, Inc. is a biomaterials and bioengineering company based in Nashville, Tennessee, with an additional office in Houston, Texas. Established in 2017, the company specializes in developing bioresorbable smart polymers aimed at enhancing vascular surgery outcomes. Its primary product, SelfWrap, is a perivascular wrap designed to minimize complications at the junctions of veins and arteries, particularly for dialysis patients. SelfWrap functions as an external stent that promotes outward vein growth and provides mechanical support, thereby reducing the risk of vein collapse. By focusing on innovative solutions in vascular care, VenoStent aims to improve patient outcomes and transform surgical practices.

Cognition Therapeutics

Series B in 2015
Cognition Therapeutics, Inc. is a clinical-stage neuroscience company based in Pittsburgh, Pennsylvania, focused on developing small molecule therapeutics aimed at addressing neurodegenerative and neuro-ophthalmic disorders. Founded in 2007, the company is notable for its drug candidate CT1812, an oral brain-penetrant molecule designed to restore cellular processes disrupted by diseases such as Alzheimer’s and dry age-related macular degeneration. Cognition Therapeutics targets the toxic proteins that contribute to cognitive decline, a key factor in various degenerative diseases of the brain. The company employs proprietary assays and medicinal chemistry to create novel, high-quality drug candidates, addressing an unmet need in the treatment of these complex conditions.

Wisegate

Series B in 2014
Wisegate is an IT research service that connects senior technology professionals, allowing them to share information and insights without external influences from analysts, vendors, or media. By employing a crowdsourcing model, Wisegate provides users with access to authentic intelligence derived from the collective knowledge and experiences of their peers. The platform enables IT professionals to receive practical advice and fast answers through a curated website that fosters content sharing and collaboration. Wisegate's focus is on delivering honest, pragmatic information based on real-world experiences, ensuring that users benefit from direct insights without the biases typically found in traditional advisory services. This approach positions Wisegate as a valuable resource for seasoned IT leaders seeking reliable guidance in their decision-making processes.

Encore Vision

Angel Round in 2013
Encore Vision is a Fort Worth, Texas-based company specializing in the design and supply of eyewear products, including lenses, frames, and health technology equipment. The company is focused on developing innovative treatments for presbyopia, leveraging extensive mentorship from ophthalmologists and optometrists during its early stages. Encore Vision has made significant strides in securing intellectual property protection, boasting a robust patent portfolio that includes an issued U.S. patent, a notice of allowance for a second patent, and over 40 pending applications in the U.S. and internationally. The company has successfully completed in-vivo proof of concept studies in animal models and is progressing towards clinical studies in humans. Established in 2000, Encore Vision continues to advance its technology and products in the eyewear industry.

Wisegate

Series A in 2013
Wisegate is an IT research service that connects senior technology professionals, allowing them to share information and insights without external influences from analysts, vendors, or media. By employing a crowdsourcing model, Wisegate provides users with access to authentic intelligence derived from the collective knowledge and experiences of their peers. The platform enables IT professionals to receive practical advice and fast answers through a curated website that fosters content sharing and collaboration. Wisegate's focus is on delivering honest, pragmatic information based on real-world experiences, ensuring that users benefit from direct insights without the biases typically found in traditional advisory services. This approach positions Wisegate as a valuable resource for seasoned IT leaders seeking reliable guidance in their decision-making processes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.